Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Novartis Collaboration Brings Combined Strength To NASH Development

Executive Summary

Combination therapy is expected to prevail in NASH. Pfizer and Novartis, while trailing smaller companies, are studying their candidates together in hopes of hitting on a winning combo for the multi-factorial disease.

Advertisement

Related Content

Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs
Finance Watch: Investors Can't Get Enough Of NASH, Including Start-Ups With Novel Drugs
Pfizer Working To Catch Up In NASH With Fat-Reducing Compounds
Could High Profile Combo Be Allergan/Novartis Answer To Late-Stage NASH Programs?
Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground
In Novartis, Conatus Lands Experienced, Deep-Pocketed NASH Partner
Combination Strategies A Common Thread In NASH R&D

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124080

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel